BioWorld Asia

Feb. 11, 2004

Ark Seeks Listing On London Stock Exchange Via £50 IPO

LONDON - Ark Therapeutics Group plc is feeling out investor appetite for what would be the first listing of a biotechnology company on the main market of the London Stock Exchange in three years. (BioWorld International) Read More

CAT Reports CAT-192 Results With Genzyme, Ends Elan Deal

Structure Of 1918 Flu Virus Holds Clue To Its Virulence

Hurdles For Europe Include Tissue Engineering, Patents

Advancements In SiRNA Spur Strategy Change For Atugen

BiondVax Raises $4M For Multiseason Nasal Vaccine

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...